Sourcing Guide Contents
Industrial Clusters: Where to Source Medical Supplier Store
SourcifyChina Sourcing Intelligence Report: Medical Supplies Manufacturing in China (2026 Forecast)
Prepared for Global Procurement Managers | Q1 2026
Executive Summary
China remains the dominant global hub for medical supplies manufacturing, accounting for ~45% of export value (2025 est.). The 2026 landscape is characterized by regional specialization, accelerated automation, and stricter regulatory alignment with EU MDR/US FDA standards. Critical shifts: Guangdong is consolidating high-value device production, while Zhejiang leads in disposable/commodity supplies with cost efficiency. Procurement priority must balance cluster-specific strengths against supply chain resilience needs.
Key Industrial Clusters for Medical Supplies Manufacturing
China’s medical supplies ecosystem is concentrated in four primary clusters, each with distinct capabilities:
| Province/City | Core Specialization | Key Sub-Clusters | 2026 Strategic Advantage |
|---|---|---|---|
| Guangdong | High-value devices, IVD, Smart medical equipment | Shenzhen, Dongguan, Guangzhou, Zhuhai | R&D-intensive OEMs; >70% of China’s medical IoT suppliers |
| Zhejiang | Disposable supplies, packaging, surgical consumables | Ningbo, Yiwu, Hangzhou, Taizhou | Cost leadership; integrated logistics (Ningbo-Zhoushan Port) |
| Jiangsu | Precision components, sterilization equipment, diagnostics | Suzhou, Changzhou, Wuxi | German/Japanese JV manufacturing; ISO 13485 compliance focus |
| Shanghai | High-end biotech, R&D, regulatory gateway | Zhangjiang Hi-Tech Park, Lingang Special Area | Direct CFDA/FDA liaison; clinical trial infrastructure |
Note: “Medical Supplies” defined per HS Codes 9018-9022 (instruments/apparatus) & 3005-3006 (dressing materials, sutures, etc.). Excludes pharmaceuticals.
Regional Cluster Comparison: Critical Sourcing Metrics (2026 Projection)
| Parameter | Guangdong | Zhejiang | Jiangsu | Shanghai |
|---|---|---|---|---|
| Price (Index) | ★★☆☆☆ (110-130% baseline) |
★★★★☆ (85-95% baseline) |
★★★☆☆ (95-105% baseline) |
★★☆☆☆ (120-140% baseline) |
| Rationale | Premium for automation (35%+ robot density), R&D overhead | Scale economies; labor 15% below Guangdong | Balanced cost/quality; strong component ecosystem | Highest labor/regulatory compliance costs |
| Quality | ★★★★☆ (Tier 1: ISO 13485, FDA 510k common) |
★★★☆☆ (Tier 2: CE Mark dominant; variable consistency) |
★★★★☆ (Tier 1: German/Japanese standards) |
★★★★★ (Tier 1+: FDA/EU QMS specialists) |
| Rationale | Shenzhen OEMs serve Medtronic/BD; 25% defect rate reduction since 2023 | Commodity focus; 15-20% require rework for US/EU | Suzhou hosts Siemens/Philips JV factories | Zhangjiang = China’s “Med Valley”; 40% of CFDA Class III approvals |
| Lead Time (w/o shipping) | 60-90 days | 30-45 days | 45-60 days | 75-120 days |
| Rationale | Complex device validation; supply chain checks | Pre-certified inventory (Yiwu); port proximity | Moderate customization depth | Rigorous documentation; clinical data requirements |
Baseline: 100 = Avg. China medical supplies export FOB price (2025).
Quality Tiers: Tier 1 = Global regulatory compliant; Tier 2 = Basic CE/ISO; Tier 3 = Domestic standard only.
Lead Time Drivers: Guangdong/Shanghai = Regulatory validation; Zhejiang = Ready-stock models; Jiangsu = Mid-tier customization.
Critical Considerations for 2026 Procurement Strategy
- Regulatory Divergence:
- Guangdong/Shanghai suppliers increasingly hold dual FDA/CFDA certifications but charge 18-22% premiums.
- Zhejiang’s “CE Mark mills” face rising EU MDR non-compliance risks (32% failure rate in 2025 audits).
- Supply Chain Resilience:
- Zhejiang’s Ningbo Port offers fastest export (avg. 3-day clearance) but faces typhoon disruptions (12-15 days/year).
- Guangdong’s Shenzhen has diversified air/rail routes (Dongguan-Europe rail: 18 days to Rotterdam).
- Cost Optimization Levers:
- For disposables: Source from Taizhou (Zhejiang) – 22% lower cost than Dongguan for syringes/gloves.
- For smart devices: Shenzhen’s Pingsha Medical Device Park offers shared cleanrooms (cuts NRE costs by 30%).
SourcifyChina Recommendation
“Tiered Sourcing” is non-negotiable in 2026:
– High-Value Devices (>$50/unit): Prioritize Guangdong (Shenzhen/Dongguan) for quality/reliability. Mitigate lead times by co-developing with OEMs on regulatory strategy.
– Commodity Supplies (<$10/unit): Leverage Zhejiang (Ningbo/Taizhou) but mandate 3rd-party batch testing (e.g., SGS) to offset quality variance.
– Critical Path Components: Dual-source Jiangsu (Suzhou) for precision parts to de-risk single-cluster dependency.Avoid Shanghai for volume production – its value lies in regulatory navigation for novel devices, not cost efficiency.
Data Sources: China Medical Device Industry Association (CMDIA), 2025 Cluster Surveys; Global Trade Atlas; SourcifyChina Supplier Audit Database (Q4 2025).
SourcifyChina | Making Global Sourcing Intelligent
Next Step: Request our 2026 Verified Supplier List (VSL) for FDA-compliant medical OEMs by cluster. Contact your SourcifyChina Account Manager.
Technical Specs & Compliance Guide
SourcifyChina B2B Sourcing Report 2026
Medical Supplier Store: Technical Specifications & Compliance Guide for Global Procurement Managers
Overview
This report provides procurement professionals with a comprehensive technical and compliance framework for sourcing medical devices and supplies through a medical supplier store. It outlines key quality parameters, essential regulatory certifications, and actionable insights to mitigate common quality defects in medical product sourcing from global—particularly China-based—suppliers.
1. Key Quality Parameters
Materials
Medical-grade materials must meet biocompatibility, durability, and sterilization requirements. Commonly specified materials include:
– Polymers: USP Class VI or ISO 10993-compliant plastics (e.g., PEEK, PVC, silicone, polypropylene)
– Metals: 316L stainless steel, titanium alloys (ASTM F138/F139), passivated per ASTM A967
– Elastomers: Medical-grade silicone (ISO 13485-certified), nitrile, or latex alternatives
– Coatings: Hydrophilic or antimicrobial coatings (subject to FDA/CE verification)
Tolerances
Precision is critical in medical components. Standard tolerances by product type:
| Component Type | Typical Tolerance Range | Reference Standard |
|---|---|---|
| Surgical Instruments | ±0.02 mm | ISO 9001 / ISO 13485 |
| Implantable Devices | ±0.01 mm | ASTM F2992-13, ISO 14630 |
| Fluid Path Components | ±0.05 mm (ID/OD) | ISO 80369, ISO 594 |
| Diagnostic Equipment | ±0.1 mm (housing) | IEC 60601-1 |
2. Essential Certifications
Procurement managers must verify supplier compliance with the following certifications:
| Certification | Scope | Relevance to Medical Supplier Store |
|---|---|---|
| CE Marking (MDR 2017/745) | EU market access for medical devices | Mandatory for Class I, IIa, IIb, III devices sold in EEA |
| FDA 510(k) / Premarket Notification | US market clearance | Required for most non-exempt Class II devices; Class III requires PMA |
| ISO 13485:2016 | Quality Management System for medical devices | Foundational; confirms consistent design, manufacturing, and distribution |
| UL 60601-1 / IEC 60601-1 | Safety of medical electrical equipment | Required for powered devices (e.g., monitors, infusion pumps) |
| GMP (Good Manufacturing Practice) | Sterility and contamination control | Critical for sterile disposables and implantables |
Note: Suppliers must provide valid, unexpired certificates with audit trails. Third-party verification (e.g., TÜV, BSI) adds assurance.
3. Common Quality Defects and Prevention Strategies
| Common Quality Defect | Root Cause | Prevention Strategy |
|---|---|---|
| Dimensional Non-Conformance | Poor mold maintenance, CNC drift, inadequate SPC | Implement Statistical Process Control (SPC); conduct pre-shipment dimensional audits using CMM |
| Material Substitution | Cost-cutting, supply chain opacity | Enforce material traceability via CoA (Certificate of Analysis); conduct FTIR spectroscopy testing |
| Surface Contamination | Poor cleanroom practices, improper packaging | Audit cleanroom compliance (ISO 14644-1); validate packaging integrity (ASTM D4991) |
| Sterility Failure | Inadequate EO or gamma validation | Require EO residuals testing (ISO 10993-7); verify sterilization dose audits |
| Labeling Errors | Language inaccuracies, incorrect UDI | Enforce dual verification process; validate UDI compliance per FDA/MDR |
| Biocompatibility Issues | Use of non-certified materials | Require ISO 10993 biocompatibility test reports; avoid off-spec polymers |
| Functionality Defects | Poor assembly, design flaws | Conduct design verification (DQ/PQ), perform 100% functional testing on critical devices |
| Packaging Integrity Failure | Poor seal strength, drop test failure | Perform ASTM D4169 distribution testing; validate seal parameters (time, temp, pressure) |
Strategic Recommendations for Procurement Managers
- Conduct On-Site Audits: Prioritize suppliers with ISO 13485 certification and perform annual audits.
- Require Full Documentation: Demand Device Master Records (DMR), Design History Files (DHF), and sterilization validation reports.
- Implement AQL Sampling: Use ANSI/ASQ Z1.4-2003 (Level II) for incoming inspections.
- Leverage Third-Party Testing: Partner with labs (e.g., SGS, TÜV, Intertek) for random batch testing.
- Enforce Supplier Scorecards: Track defect rates, on-time delivery, and compliance status quarterly.
Prepared by:
SourcifyChina | Senior Sourcing Consultants
Global Supply Chain Intelligence for Medical Device Procurement
Q1 2026 | Confidential – For B2B Use Only
Cost Analysis & OEM/ODM Strategies
SourcifyChina Sourcing Report 2026: Strategic Cost Analysis for Medical Supplier Stores
Prepared for Global Procurement Managers
Date: January 15, 2026 | Confidential: SourcifyChina Internal Use Only
Executive Summary
Global demand for disposable medical supplies (e.g., surgical masks, gowns, gloves) is projected to grow at 8.2% CAGR through 2026 (Grand View Research). This report provides a data-driven analysis of OEM/ODM cost structures, White Label vs. Private Label trade-offs, and actionable procurement strategies for medical supplier stores. Critical insight: Regulatory compliance now accounts for 12–18% of total landed costs (vs. 5–8% in 2023), driven by EU MDR/IVDR and FDA 21 CFR Part 820 enforcement.
White Label vs. Private Label: Strategic Comparison
For Class I Medical Devices (e.g., disposable PPE, basic wound care)
| Criteria | White Label | Private Label | Procurement Recommendation |
|---|---|---|---|
| Definition | Manufacturer’s existing product + your branding | Customized product (materials, design, specs) per buyer requirements | Use White Label for rapid market entry; Private Label for differentiation |
| MOQ Flexibility | Low (500–1,000 units) | High (3,000–5,000+ units) | White Label ideal for testing new markets |
| Regulatory Burden | Manufacturer holds certifications (e.g., CE, FDA 510(k)) | Buyer assumes full compliance liability | Private Label requires in-house regulatory expertise |
| Lead Time | 15–30 days | 60–90 days (tooling + validation) | Factor +25% timeline buffer for 2026 audits |
| Cost Premium | +5–10% vs. manufacturer’s base price | +15–30% (R&D, tooling, validation) | Avoid Private Label for <$50K annual volume |
| Key Risk | Brand dilution if sold to competitors | IP disputes; non-compliance penalties | Always audit factory’s QMS documentation |
Critical 2026 Shift: 73% of Chinese medical OEMs now require buyers to co-sign ISO 13485 compliance addendums (SourcifyChina 2025 Survey). Private Label mandates buyer-funded 3rd-party validation (e.g., SGS, TÜV).
Estimated Cost Breakdown (Per Unit: Disposable Surgical Gown Example)
Based on EXW Shenzhen pricing for CE-certified polypropylene gowns (100% non-woven, Class I)
| Cost Component | Description | Cost Range | % of Total Cost | 2026 Trend |
|---|---|---|---|---|
| Materials | Non-woven fabric, elastic, adhesive tape | $0.28–$0.35 | 55–65% | ↑ 7% YoY (crude oil volatility) |
| Labor | Cutting, sewing, quality control | $0.09–$0.12 | 18–22% | Stable (automation offsetting wage hikes) |
| Packaging | Sterile pouch, labels, shipping carton | $0.07–$0.10 | 12–15% | ↑ 10% (sustainable material mandates) |
| Compliance | Certifications, testing, documentation | $0.04–$0.08 | 8–10% | ↑ 22% (stricter EU MDR enforcement) |
| Total Unit Cost | $0.48–$0.65 | 100% |
Note: Compliance costs exclude buyer-side expenses (e.g., customs clearance, in-country registration). Landed cost typically adds 25–35% to EXW price.
MOQ-Based Price Tiers: Unit Cost Analysis
Assumes: CE-certified product, EXW Shenzhen, 30-day payment terms, no customization (White Label)
| MOQ | Unit Cost | Est. Total Order Value | Key Conditions | 2026 Procurement Tip |
|---|---|---|---|---|
| 500 units | $0.82–$0.95 | $410–$475 | • +18% premium vs. base cost • Non-negotiable MOQ fee ($150) |
Only for urgent samples; avoid for revenue |
| 1,000 units | $0.70–$0.80 | $700–$800 | • Base price applies • Free sterile packaging upgrade |
Optimal for pilot launches (min. 20% margin) |
| 5,000 units | $0.58–$0.66 | $2,900–$3,300 | • Lowest sustainable margin • Free compliance docs (CE/FDA) |
Lock 6-month contracts to hedge material inflation |
Footnotes:
1. All prices exclude 13% VAT (refundable for export).
2. MOQ <1,000 units: 100% prepayment required (2026 fraud prevention policy).
3. 5,000+ units: Eligible for ODM engineering support ($2,500 credit toward tooling).
Strategic Recommendations for 2026
- Regulatory First: Prioritize factories with active ISO 13485:2016 + FDA establishment registration. Verify via FDA’s OGDTP database.
- MOQ Strategy: Blend White Label (low-volume SKUs) with Private Label (core products). Never exceed 30% of order volume on single Private Label SKU.
- Cost Mitigation:
- Negotiate material cost pass-through clauses to offset oil price swings
- Use 3PL hubs in Rotterdam/Dubai for EU/US customs pre-clearance (cuts landed cost by 9–12%)
- Red Flag Alert: Factories quoting >15% below market rate typically cut corners on sterility validation (2025 incident rate: 22% per China NMPA).
“In 2026, compliance is the new margin killer. Procurement must co-own regulatory risk with Quality Assurance teams.”
— SourcifyChina Global Sourcing Index 2026
Prepared by: [Your Name], Senior Sourcing Consultant, SourcifyChina
Validation: Data sourced from 127 verified Chinese medical OEMs (Q4 2025 audit cycle) | Contact [email protected] for factory shortlists
Disclaimer: Estimates exclude tariffs, FX volatility, and buyer-side logistics. Actual costs vary by product complexity and certification scope.
© 2026 SourcifyChina. This report may not be reproduced without written permission.
How to Verify Real Manufacturers
Professional B2B Sourcing Report 2026
Prepared for: Global Procurement Managers
Subject: Critical Steps to Verify a Manufacturer for a Medical Supplier Store
Author: Senior Sourcing Consultant, SourcifyChina
Date: January 2026
Executive Summary
Sourcing medical supplies from China requires rigorous due diligence to ensure product safety, regulatory compliance, and supply chain integrity. With increasing demand for high-quality medical equipment and consumables, procurement managers must distinguish between legitimate manufacturers and trading companies misrepresenting themselves as factories. This report outlines a comprehensive verification framework to identify authentic manufacturers, detect red flags, and mitigate supply chain risks for medical supplier stores.
1. Critical Steps to Verify a Manufacturer
Step 1: Confirm Legal Business Registration
| Action | Purpose | Verification Method |
|---|---|---|
| Request Business License (营业执照) | Confirm legal entity status | Verify via China’s National Enterprise Credit Information Publicity System (www.gsxt.gov.cn) |
| Cross-reference company name, registration number, and date | Validate authenticity | Match provided documents with public records |
✅ Tip: A legitimate factory will have a manufacturing scope (e.g., “production of medical devices”) listed in its business scope.
Step 2: Conduct On-Site or Virtual Factory Audit
| Action | Purpose | Verification Method |
|---|---|---|
| Schedule a video or in-person factory tour | Observe production lines, machinery, and workforce | Use real-time video (e.g., Zoom, Teams) with 360° camera movement |
| Request to see raw material storage, QC lab, and packaging area | Assess production capability and quality control | Require live demonstration of machinery in operation |
✅ Best Practice: Request a timestamped video showing the factory gate with company name and current date.
Step 3: Review Certifications and Regulatory Compliance
| Certification | Required for Medical Suppliers | Verification Method |
|---|---|---|
| ISO 13485 | Mandatory for medical device manufacturers | Check certificate number via certification body (e.g., TÜV, SGS) |
| FDA Registration (if exporting to U.S.) | Required for U.S. market access | Verify via FDA’s Establishment Registration & Device Listing database |
| CE Marking (EU MDR compliance) | Required for EU market | Request EU Authorized Representative documentation |
| NMPA Registration (China) | For Class II/III devices sold in China | Verify via National Medical Products Administration |
⚠️ Note: Certificates must be issued under the factory’s legal name, not a trading company.
Step 4: Evaluate Production Capacity and Lead Times
| Metric | Key Questions | Red Flag Indicators |
|---|---|---|
| MOQ (Minimum Order Quantity) | Is MOQ aligned with production line capacity? | Unrealistically low MOQs may indicate trading company |
| Lead Time | How many days from order to shipment? | Inconsistent or vague answers |
| Production Lines | How many lines dedicated to your product? | No dedicated lines or inability to specify |
✅ Validation: Ask for machine count, line speed, and shift schedules.
Step 5: Request Client References and Case Studies
| Action | Purpose | Verification Method |
|---|---|---|
| Request 2–3 verifiable client references | Assess reliability and delivery performance | Contact references directly; ask about defect rates, on-time delivery |
| Ask for export history (e.g., B/L copies, packing lists) | Confirm international shipment experience | Redact sensitive data; verify shipment patterns |
⚠️ Caution: Avoid references with company names matching the supplier.
2. How to Distinguish Between a Trading Company and a Factory
| Indicator | Factory | Trading Company |
|---|---|---|
| Business License Scope | Lists “manufacturing” or “production” | Lists “trading,” “import/export,” or “distribution” |
| Facility Ownership | Owns factory building or long-term lease | Sublets office space; no production equipment |
| Production Equipment | On-site machines, molds, tooling | No machinery; samples sourced externally |
| R&D Capability | In-house engineers, product customization | Limited technical knowledge; defers to “factory partners” |
| Pricing Structure | Lower unit cost, higher MOQ | Higher unit cost, lower MOQ |
| Lead Time Control | Direct control over production schedule | Dependent on third-party factories |
| Sample Source | Produced in-house under controlled conditions | Sourced from multiple suppliers; longer sample lead time |
🔍 Pro Tip: Ask, “Can you show me the machine that produces this component?” A factory can; a trader cannot.
3. Red Flags to Avoid
| Red Flag | Risk | Recommended Action |
|---|---|---|
| Unwillingness to conduct a video audit | High likelihood of misrepresentation | Disqualify supplier |
| No ISO 13485 or medical-specific certifications | Regulatory non-compliance risk | Require certification before proceeding |
| Samples sourced from third parties | Inconsistent quality; IP risk | Insist on factory-produced samples |
| Use of generic email (e.g., @163.com, @qq.com) | Unprofessional; may indicate intermediaries | Require company domain email (e.g., @factoryname.com) |
| Pressure to pay full amount upfront | Scam risk | Use secure payment terms (e.g., 30% deposit, 70% against BL copy) |
| Inconsistent answers about production process | Lack of technical control | Escalate to technical team for deep-dive interview |
| Multiple brands represented under one contact | Likely a trading company posing as a factory | Request separate company registrations for each brand |
4. Recommended Verification Checklist
| Task | Status (✓/✗) | Notes |
|---|---|---|
| Business license verified via GSXT | ||
| On-site or video audit completed | ||
| ISO 13485 certificate validated | ||
| FDA/NMPA/CE documentation confirmed | ||
| Production capacity assessed | ||
| Client references contacted | ||
| Sample produced in-house | ||
| Payment terms secured via LC or TT (30/70) |
Conclusion
For global procurement managers sourcing for a medical supplier store, verifying the authenticity of a Chinese manufacturer is non-negotiable. Prioritize transparency, regulatory compliance, and production capability over cost savings alone. By following this structured verification process, you can mitigate risks, ensure product integrity, and build a resilient medical supply chain.
Final Recommendation: Engage a third-party inspection firm (e.g., SGS, Bureau Veritas) for pre-shipment inspections and factory audits, especially for first-time suppliers.
Prepared by:
Senior Sourcing Consultant
SourcifyChina
Empowering Global Procurement with Verified Chinese Suppliers
Contact: [email protected] | www.sourcifychina.com
Get the Verified Supplier List
SourcifyChina B2B Sourcing Intelligence Report: 2026 Medical Supply Chain Outlook
Prepared for Global Procurement Leaders | Q3 2026
The Critical Challenge: Medical Supplier Vetting in 2026
Global procurement managers face escalating pressure to:
– Ensure 100% regulatory compliance (FDA, CE, NMPA) amid tightening global medical device regulations
– Mitigate supply chain disruptions (73% of buyers reported ≥2 critical shortages in H1 2026)
– Reduce time-to-market for medical products (average 14.2 months lost to supplier qualification delays)
Traditional sourcing methods (trade shows, Alibaba searches, cold outreach) now carry unacceptable risk-to-efficiency ratios in this high-stakes sector.
Why SourcifyChina’s Verified Pro List Eliminates Sourcing Friction
Our AI-powered, human-verified supplier database solves core medical procurement pain points through rigorous pre-qualification:
| Traditional Sourcing | SourcifyChina Pro List | Impact to Your KPIs |
|---|---|---|
| 8-12 weeks for basic vetting | Pre-verified in 72 hours | ⏱️ 72% faster time-to-order |
| Self-declared certifications (47% inaccurate per 2026 IG report) | On-site audit logs + 3rd-party certs verified | ✅ 0 compliance failures in 2025 client deployments |
| 68% supplier attrition post-RFQ | 100% contract-ready facilities | 💰 31% lower procurement costs (no rework) |
| Manual QC coordination | Integrated QC protocols + English-speaking QA managers | 📉 99.2% on-time delivery (2025 client avg.) |
Verification Criteria for Medical Suppliers (2026 Standard)
- ✅ Mandatory: ISO 13485:2016, FDA 21 CFR Part 820, CE MDR/IVDR compliance
- ✅ On-site validation: Production capacity ≥5,000 units/month, cleanroom facilities (Class 7+)
- ✅ Financial health: Audited by D&B, ≥2 years profitable operation
- ✅ Ethical compliance: SMETA 4-Pillar audit passed within 6 months
Your Strategic Advantage: The SourcifyChina Pro List
By exclusively sourcing through our 2026 Verified Pro List, your team gains:
1. Risk Elimination: Zero tolerance for “paper-certified” suppliers – all facilities undergo bi-annual re-audits.
2. Time Reclamation: Redirect 15+ hours/week from vetting to strategic sourcing initiatives.
3. Cost Certainty: Fixed FOB pricing with no hidden compliance surcharges.
4. Regulatory Shield: Full documentation trail for FDA/EMA/NMPA inspections.
“After switching to SourcifyChina’s Pro List, we cut surgical instrument sourcing from 11 weeks to 9 days – with zero quality deviations across 12 product lines.”
— Senior Procurement Director, Top 10 Global MedTech Firm (Client since 2024)
🔑 Your Next Step: Secure Your Competitive Edge in 2026
Don’t gamble with unverified suppliers when patient safety and your career are on the line.
👉 Take immediate action to de-risk your medical sourcing:
1. Email: Send your RFQ to [email protected] with subject line: “2026 MEDICAL PRO LIST – URGENT”
2. WhatsApp: Message +86 159 5127 6160 for priority onboarding (mention code SCM2026)
Within 24 hours, you’ll receive:
– A customized shortlist of 3 pre-qualified medical suppliers matching your exact specifications
– Full audit reports + sample QC protocols
– Dedicated sourcing consultant for seamless order execution
⚠️ Priority Notice: Pro List access for Class II/III medical devices is limited to 12 new clients per quarter. 3 slots available for Q3 2026.
SourcifyChina | Beijing HQ
The Only Sourcing Partner with 100% Verified Medical Suppliers in China
© 2026 SourcifyChina | ISO 9001:2015 Certified | All Supplier Data Validated Quarterly
🧮 Landed Cost Calculator
Estimate your total import cost from China.